#### **ORIGINAL PAPER**



# **Diagnostic performance of shear wave elastography in discriminating malignant and benign breast lesions**

**Our experience with QelaXtoTM software**

Karina Pesce<sup>1</sup><sup>®</sup> [·](http://orcid.org/0000-0002-0514-0243) Fernando Binder<sup>2</sup> · María José Chico<sup>1</sup> · María Paz Swiecicki<sup>1</sup> · Diana Herbas Galindo<sup>1</sup> · **Sergio Terrasa3**

Received: 14 February 2020 / Accepted: 14 May 2020 / Published online: 11 June 2020 © Società Italiana di Ultrasonologia in Medicina e Biologia (SIUMB) 2020

### **Abstract**

**Study aims** We sought to evaluate the diagnostic performance of quantitative elastography (shear wave elastography) and to establish the optimal cutoff value to differentiate malignant and benign breast lesions using QelaXtoTM software.

**Methods** We conducted a retrospective observational study of adult women with suspicious breast lesions (BIRADS 3, 4 or 5) who underwent programmed ultrasound-guided core biopsies. Breast lesions were assessed using quantitative elastography combined with B-mode ultrasound. Histopathology was used as reference standard. Sensitivity, specifcity, positive predictive value (PPV) and negative predictive value (NPV) were estimated, and a ROC curve analysis was conducted. Three elastography cutoff values were considered: 36, 50 and 80 kPa.

**Results** We included 143 women (mean age of 56 years) with a total of 145 breast lesions: 68 benign tumors (47.26%) and 77 malignancies (52.74%). Mean elasticity measurements of benign and malignant lesions were signifcantly diferent (24.6 kPa, SD 28.47, vs. 101.49 kPa, SD 47.38,  $p < 0.0001$ ). Using the 50 kPa cutoff, elastography showed a global sensitivity of 87% to discriminate malignant lesions (AUC = 0.897). Moreover, sensitivity was 90.7% when lesions were located 5–40 mm below the skin surface (optimal elastographic feld of view). Our false positive rate was 17.65%, comprised mainly of fbroepithelial neoplasms, fbroadenomas and fbrosis.

**Conclusions** Quantitative elastography can diferentiate malignant and benign breast lesions with acceptable to excellent performance. In our sample, the QelaXtoTM software showed a lower optimal cutof than other ultrasound systems.

**Keywords** Elastography · Breast cancer · Mammary ultrasonography · Elasticity imaging techniques

# **Introduction**

Elastography, an imaging modality that evaluates the elastic properties or hardness of tissues, has shown potential in the assessment and characterization of breast lesions  $[1,$  $[1,$ 

 $\boxtimes$  Karina Pesce drakarina.pesce@gmail.com; karina.pesce@hospitalitaliano.org.ar

- <sup>1</sup> Breast Imaging and Interventional Radiology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
- <sup>2</sup> Department of Health Informatics, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
- <sup>3</sup> Research Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

[2](#page-8-0)]. Elastography measures small tissue displacements as external pressure is applied. Since displacement is inversely related to tissue stifness, malignant lesions—often harder in consistency—tend to show less displacement than benign lesions or normal tissue [[3](#page-8-1), [4\]](#page-8-2). There are two main methods to evaluate tissue elasticity: strain elastography (qualitative) and shear wave elastography (quantitative) [[2,](#page-8-0) [5\]](#page-8-3).

Qualitative elastography offers a color-coded strain map, which depicts diferent tissue displacement patterns (elastographic patterns). This map is overlaid on gray-scale B-mode ultrasound images, facilitating the spatial interpretation of elastographic fndings. Qualitative elastography's main disadvantages are its operator dependency (subjective interpretation of the color map), considerable inter- and intraobserver variability and a prolonged learning curve

(a 3–6 month training period is usually required to obtain reproducible results) [\[2](#page-8-0), [5](#page-8-3)[–8](#page-8-4)].

To overcome these limitations, shear wave elastography (SWE) was introduced in the market. This method uses acoustic waves to induce mechanical vibrations and quantifes the stifness of a lesion by capturing and analyzing propagated shear waves. The speed of shear wave propagation is directly related to the hardness of the evaluated tissue. Tissue elasticity is measured in kilopascals (kPa) or meters per second (m/s) [\[7](#page-8-5), [9\]](#page-8-6), with values ranging from 0 to 180 kPa (higher values of quantitative elastography were associated with higher risk of malignancy) [[7](#page-8-5)[–16\]](#page-8-7). Quantitative elastography has shown promising results in several felds [\[17–](#page-8-8)[20\]](#page-8-9), and it could play a role in the early characterization of breast lesions, particularly BIRADS 3 and 4-A [\[21](#page-8-10)].

Even though three systematic reviews have evaluated the operational characteristics of quantitative elastography [[22–](#page-8-11)[24](#page-8-12)], most of them have used Toshiba and Siemens Ultrasound systems, and to this date we have not found publications establishing optimal elastography cutoff values for the QelaXtoTM software in patients with breast lesions.

*Study aims* We sought to evaluate the diagnostic performance of quantitative elastography and to establish the optimal cutoff value to differentiate between malignant and benign breast lesions using an Esaote MyLab Eight Ultrasound system.

# **Methods**

#### **Study design**

We conducted a retrospective observational study of diagnostic tests performed on a consecutive sample of women with breast lesions who attended the Breast Imaging and Interventional Radiology Department in a 3rd level academic hospital in Buenos Aires, between May and September 2018.

### **Setting**

This study was conducted at a third level academic hospital with centralized electronic health records. The Breast Imaging and Interventional Radiology Department is comprised of 10 specialists and 2 fellows, all of whom are exclusively dedicated to breast imaging. On average, the department reports 30,000 mammograms and conducts 25,000 breast ultrasounds annually. It possesses an integrated RIS/ PACS system since 2010.

#### **Study participants**

Our study included women over 18 years of age who underwent a programmed ultrasound-guided breast core biopsy due to a suspicious breast mass. We included lesions categorized as low- (BIRADS 3), medium- (BIRADS 4A, B or C) or highly suspicious of malignancy (BIRADS 5) by a previous ultrasound, according to the 5th BIRADS edition [\[25](#page-8-13)]. We excluded women with incomplete histopathology reports.

#### **Index diagnostic test: quantitative elastography**

The index diagnostic test was quantitative elastography (SWE) performed in combination with B-mode ultrasound, using an Esaote MyLab Eight Ultrasound System (Esaote, Genova, Italy). The Breast Imaging and Interventional Radiology Department at our institution uses a linear array transducer with a frequency range of 7.5–15 MHz and the Qelaxto software for quantitative evaluation of tissue stifness. Elastographic evaluations of breast lesions are performed by four medical imaging specialists with exclusive dedication to breast imaging.

Using B-mode ultrasound, radiologists record lesion features such as lesion size (maximum diameter), length of breast tissue containing the suspicious lesion (vertical distance from the skin to the pectoralis muscle) and lesion depth (vertical distance from the skin to the upper margin of the nodule). Nodule stifness is evaluated following the elastography protocol summarised in Table [1](#page-1-0). According to published evidence, the harder the lesion measured with quantitative elastography (in kPa), the higher the probability of malignancy.

Given that SWE was performed before biopsy specimens were obtained, physicians performing SWE were blind to histopathologic results (reference standard).

<span id="page-1-0"></span>**Table 1** Summarized protocol for quantitative elastography combined with B-mode breast ultrasound for the evaluation of BIRADS 3, BIRADS 4 (A, B and C) and BIRADS 5 lesions at the Breast Imaging and Interventional Radiology Department

Field of view (FoV) delimitation: FoV must include part of the lesion and at least 3 mm of normal adjacent breast tissue

The transducer is immobilized over the breast for 5–10 s to stabilize the image. Immediately after asking the patient to hold their breath, elastographic measurements are taken

Every nodule is measured in at least ten diferent areas. Mean elasticity, expressed in kiloPascals, is recorded

When the distance between the nodule and the skin surface is less than 5 mm, a thick coat of gel is applied between the transducer and the patient's skin, to increase the distance between the transducer and the lesion. This allows a better inclusion of the nodule in the feld of view (the Software has a fxed feld of view that does not include lesions closer than 5 mm or below 50 mm)

<span id="page-2-1"></span>**Table 2** Baseline characteristics and main lesion measurements of patients with benign and malignant histopathology results



<sup>a</sup> Ductal breast carcinoma (in situ or invasive), invasive lobular carcinoma and/or sarcoma

 $<sup>b</sup>$  *t* test for independent samples</sup>

<sup>c</sup> Nonparametric trend test

## **Reference standard test: histopathology**

Histopathology reports of breast core biopsies were retrieved from our institution's centralized electronic health records and used as reference standard.

Ultrasound-guided core needle biopsies were performed using a free-hand technique and local anesthesia, with patients in the supine position. Our team uses a reusable biopsy gun (Bard-Magnum Biopsy Instrument, Covington, GA, USA) and 14-gauge cutting needles. At our center, biopsy specimens are examined by the Pathology Department following standard histopathology procedures; samples are fxed, sectioned, stained with Haematoxylin-Eosin and evaluated by optical microscopy. At least one complete section of each core is included. When a malignant lesion is diagnosed, histologic type is assessed and nuclear grade (I, II or III) is scored. Immunohistochemistry is performed to evaluate the presence of hormone receptors (estrogen and/or progesterone receptors), Her 2 Neu receptor overexpression and Ki-67 proliferation index. Pathologists working on biopsy specimens are uninformed of elastography results.

#### **Statistical analysis**

Breast lesions were classifed into malignant and benign tumors according to their histopathology (gold standard). Every nodule with a pathology report of ductal breast carcinoma (in situ or invasive), invasive lobular carcinoma and/ or sarcoma was considered a malignant lesion.

Once the classifcation was established, the diferent elastography cutoff values were explored by ROC curve analysis. Based on systematic reviews [\[22](#page-8-11)[–24](#page-8-12)] and other publications  $[8-16, 21]$  $[8-16, 21]$  $[8-16, 21]$  $[8-16, 21]$  $[8-16, 21]$  that reported optimal elastography cutoff values between 36 and 80 kPa, our team explored three diferent cutoff values: 36, 50 and 80  $kPa<sup>1</sup>$  $kPa<sup>1</sup>$  $kPa<sup>1</sup>$ .

For each pre-specified cutoff value, we calculated sensitivity, specifcity, positive predictive value and negative predictive value with their respective 95% confdence intervals. False negative results (benign breast lesions with stifness above the elastography cutoff) were identified and their histopathology reports recorded.

STATA 13.0 software was used for data analysis.

# **Results**

#### **Study participants and breast lesions**

We identified 143 women who underwent ultrasoundguided breast biopsies due to suspicious breast lesions (BIRADS 3, 4 or 5) between May and September 2018. Mean age was 56 years. Two women had two breast lesions that met the inclusion criteria, and were included in the study sample, resulting in a total of 145 lesions evaluated with elastography (index test) and histopathology (reference standard test). 68 lesions were benign tumors (47.26%) and 77 were malignancies (52.74%). The patients' baseline characteristics and their main results are described in Table [2.](#page-2-1) Women with benign lesions were signifcantly younger than those with malignant lesions: 47.4 (SD 15.4) vs. 64.5 (SD 15.3) years of age, respectively.

Out of all 68 benign lesions, 54 (79%) were Fibroadenomas. The rest of them were fibroids  $(n = 4)$ , biphasic

<span id="page-2-0"></span><sup>1</sup> For example, Lee et al. informed that the elastographic values for malignant masses were on average 119.0  $(\pm 52.2)$  kPa and the benign lesions were 41.4 ( $\pm$ 32.1) kPa, whereas the elastographic values published by Chang et al. were slightly superior. The malignant masses had a medium elasticity of 153.3  $(\pm 58.1)$  kPa and the benign, 46.1  $(\pm 42.9 \text{ kPa})$ .



<span id="page-3-0"></span>Fig. 1 ROC curve that represents, at different cutoff values, the sensitivity and specificity of elastography for discriminating between benign and malignant tumors, considering all lesions in the study sample ( $n = 145$ ). AUC = 0.8985



<span id="page-3-1"></span>**Fig. 2** ROC curve that depicts shear wave elastography's diagnostic performance for the subset of lesions located within the optimal feld of view ( $n = 96$ ). AUC = 0.9266

lesions  $(n = 3)$ , fat necrosis  $(n = 3)$ , pseudoangiomatous stromal hyperplasia  $(n = 2)$ , and foreign body granulomas  $(n = 2)$ . Infiltrating ductal carcinomas  $(n = 62)$  were the main type of malignant lesion (81%), followed by infltrating lobular carcinoma  $(n = 10)$ , ductal carcinoma in situ  $(n = 2)$ , mucinous carcinoma  $(n = 2)$ , and breast sarcoma  $(n = 1)$ .

# **Diagnostic performance of shear wave elastography**

Overall, shear wave elastography showed acceptable to excellent discriminative ability, with an AUC of 0.898 when all lesions in our dataset were included in the analysis. Selected results of the ROC curve analysis are displayed in Figs. [1](#page-3-0) and [2](#page-3-1), and Tables [3](#page-3-2) and [4.](#page-4-0)

Figure [1](#page-3-0) depicts sensitivity and specificity estimates when all lesions are considered ( $n = 145$ , including 49 [33.8%] outside the optimal feld of view). The corresponding diagnostic performance metrics are reported in Table [3](#page-3-2).

When we considered the subset of lesions located within the optimal feld of view (96 lesions; 66.2%), AUC was 0.927. Figure [2](#page-3-1) shows a ROC curve after this second analysis and Table [4](#page-4-0) demonstrates the sensitivity, specifcity, positive and negative predictive values of elastography for the considered cutoff values, considering this subset of lesions  $(n = 96)$ .

Figure [3](#page-4-1) shows an example of a malignant lesion correctly identifed by elastography; Fig. [4,](#page-5-0) an example of a correctly identifed benign lesion.

Using the 50 kPa cutof, 10 out of 77 malignant lesions (13%) were erroneously classifed as benign (false negative results). This group included 7 infiltrating ductal carcinomas: 6 were located outside the optimal feld of view—including 2 with necrotic areas, which might yield lower elasticity measurements. The remaining false negative results were one ductal carcinoma in situ (DCIS) and 2



<sup>a</sup>The test was considered positive when the cutoff value was exceeded

<span id="page-3-2"></span>**Table 3** Sensitivity, specificity, positive predictive value and negative predictive value of prespecified elastography cutoffs for all lesions in the dataset (*n* = 145; BI-RADS 3, 4 and 5)

<span id="page-4-0"></span>**Table 4** Sensitivity, specificity, positive predictive value and negative predictive value of pre-specifed elastography cutofs for lesions located in the optimal feld of view −5 to 40  $mm (n = 96)$ 



<sup>a</sup> The test was considered positive when the cutoff value was exceeded



<span id="page-4-1"></span>**Fig. 3** 67-year-old patient. Ultrasound (**a**) revealed a solid, hypoechoic, irregular mass with spiculated margins and antiparallel orientation, at 10 o'clock position of the right breast. Length of breast tissue containing the suspicious lesion (vertical distance from the skin to the pectoralis muscle) and lesion depth (vertical distance from the skin to the upper margin of the nodule) were recorded. Quantitative elastography (**b**) showed an elasticity of 92 kPa. Histopathology report: invasive ductal carcinoma (ER+, PGR+, Her 2 Neu−, Ki 67: 10%)



**Fig. 4** 42-year-old patient with a hypoechoic solid mass, with microlobulated margins. Tissue elasticity measured by quantitative elastography was 38 kPa. Core biopsy report: involutive fbroadenoma

<span id="page-5-0"></span>mucinous carcinomas, which are typically softer than other malignant breast lesions. Figures [5](#page-6-0) and [6](#page-7-1) display lesions that yielded a false positive and false negative result, respectively.

# **Discussion**

In the evaluation of breast masses with quantitative elastography, we found a statistically significant difference between elastographic measurements of benign and malignant lesions: mean tissue stifness was 24.6 kPa (SD 28.47) vs 101.49 kPa (SD 47.38) respectively ( $p < 0.0001$ ). These outcomes are consistent with previous work by other authors [\[8](#page-8-4)–[16,](#page-8-7) [21\]](#page-8-10).

Using a 50 kPa cutoff value, elastography showed an overall sensitivity of 87% (95% CI 77–94) to detect malignant lesions (Table [2\)](#page-2-1); these results are consistent with previously reported meta-analyses [[22–](#page-8-11)[24\]](#page-8-12). Moreover, sensitivity exceeded 90% (90.7%, 95% CI 79.7–96.9) in the subgroup of lesions located between 5 and 40 mm below the skin surface (Table [3](#page-3-2)).

As for specificity, even though our overall estimate (82.35%; 95% CI 71–90) was slightly inferior than the ones reported in the previously mentioned meta-analyses [[22](#page-8-11)[–24](#page-8-12)], there is a clear overlapping of their confdence intervals: Liu and col. (86.6%; 95% CI 83.3–89.4); Xue and col. (89%; 95% CI 84–92, in caucasian population) and Luo and col. (84.9%; 95% CI 82.6–86.9).

Our false positive rate was 17.65% (95% CI 10–29), comparable to those published by Kim [[26\]](#page-8-14) and Yoon [[27](#page-8-15)], which were  $11\%$  (13–18) and 36.6% (30–44) respectively. Our false positive results were comprised of biphasic tumors, fbroadenomas and fbrosis, coinciding with other international reports  $[8-16, 21]$  $[8-16, 21]$  $[8-16, 21]$  $[8-16, 21]$ . Our global false negative rate was 13% (95% CI 6–23), which lies within the bounds reported by Suvannarerg [[8](#page-8-4)]: (12.5–17.7%) and is also comparable to those communicated by Kim [[26](#page-8-14)] and Yoon [[27\]](#page-8-15), which were 22% (12–37) and 20.6% (15–27) respectively. Most of our false negative results were located outside the optimal feld of view. The remaining false negative results consisted of a DCIS or lesions with mucinous and/or necrotic components, which are typically softer than other malignant lesions; these fndings are consistent with previous reports by the mentioned authors.

Our data suggest that the use of a gel coat between the transducer and the patient's skin (to increase the distance between the transducer and the lesion and thus include the lesion within the optimal feld of view) does not improve diagnostic performance sufficiently, since discriminative



<span id="page-6-0"></span>**Fig. 5** 45 year-old patient with a false positive result. B-mode ultrasound (**a**) showed an hypoechoic solid mass with microlobulated margins categorized as BIRADS 4A. The elastographic measurement is 54.8 kPa. Histopathology by core biopsy: biphasic tumor

ability (AUC) was higher for the subset of lesions located within the optimal feld of view.

We obtained an optimal cutoff value that is lower than the ones reported by previous studies. This fnding can probably be explained by diferent measurement equipments and/or techniques (for example, diferent software and equipments, diferent feld of view sizes, diferent number of measurements).

Our study's limitations include its reduced sample size and its retrospective design. Furthermore, women in our study sample have not undergone qualitative elastography, which might have improved our diagnostic performance if areas of the lesions whose color suggested a higher level of stifness were selected for a subsequent evaluation with quantitative elastography.

Our quantitative evaluation of SWE's diagnostic performance does not take B-mode ultrasound findings into account. Although this approach provides valid performance estimates for SWE measurements, findings should be generalized with caution, since tissue stiffness is rarely used as a standalone measure in clinical practice. Specialists usually consider both SWE and B-mode findings when evaluating suspicious lesions, as B-mode can help characterize breast lesions in various settings [[28](#page-8-16), [29\]](#page-8-17).

Furthermore, our study focused on a dichotomous classification of breast lesions (benign vs. malignant), and it did not assess the correlation of elastographic measurements with tumor histotype, grade and/or hormone receptor status.

As previously mentioned, a disadvantage of shear wave elastography with the equipment we used is that the feld of view is fxed and cannot be adjusted to measure lesions at less than 5 mm below the skin surface or deeper than 40 mm. This setback appears to be only partially solved by the use of a gel coat between the transducer and the skin.

Based on our results, which are concordant with the previously mentioned meta-analyses, quantitative elastography has shown an adequate diagnostic performance and can be an important supporting tool for the diferential diagnosis of benign and malignant breast lesions. It is a reliable, reproducible and non-invasive technique, relatively easy to perform and of low cost, given that it only requires the addition of a software package to the traditional ultrasound equipments, and it usually lasts only 5 min longer than a conventional B-mode ultrasound.



<span id="page-7-1"></span>**Fig. 6** 72-year-old patient with a false negative result. Ultrasound (**a**) showed a solid, hypoechoic, irregular mass with spiculated margins, with an antiparallel orientation at 10 o'clock position of the

# **Conclusions**

Quantitative elastography showed acceptable to excellent discriminative ability to diferentiate benign and malignant breast lesions. Most false negative results were ductal carcinomas located outside the optimal feld of view or lesions with a necrotic or mucinous component. In our study, the QelaXtoTM software showed a lower optimal cutoff value (50 kPa) than the ones reported for other ultrasound systems.

**Funding** This Study was founded by the Radiology Department of the Hospital Italiano de Buenos Aires.

# **Compliance with ethical standards**

**Conflict of interest** The authors declare no conficts of interest.

right breast. Doppler evaluation (**b**) shows peripheral vascularization. Quantitative elastography (**c**) measurement was 18.5 kPa. Histopathology report: ductal carcinoma in situ

**Ethical standards** This study was conducted in accordance with the Helsinki Declaration of 1975 and its late amendments. The study protocol was approved by the institutional Ethics Committee, with IRB approval number 3797.

**Informed consent** As we worked with de-identifed retrospective data, informed consent was waived for this retrospective study.

**Consent for publication** All authors expressed explicit consent for the publication of this manuscript.

**Code availability** Data-analysis code is available upon request.

# **References**

<span id="page-7-0"></span>1. Garra BS, Cespedes EI, Ophir J et al (1997) Elastography of breast lesions: initial clinical results. Radiology 202(1):79–86

- <span id="page-8-0"></span>2. Itoh A, Ueno E, Tohno E et al (2006) Breast disease: clinical application of US elastography for diagnosis. Radiology 239(2):341–350
- <span id="page-8-1"></span>3. Sigrist RMS, Liau J, Kafas AE, Chammas MC, Willmann JK (2017) Ultrasound elastography: review of techniques and clinical applications. Theranostics 7(5):1303–1329
- <span id="page-8-2"></span>4. Bamber J, Cosgrove D, Dietrich CF et al (2013) EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 1: basic principles and technology. Ultraschall Med 34(2):169–184
- <span id="page-8-3"></span>5. Ricci P, Maggini E, Mancuso E et al (2014) Clinical application of breast elastography: state of the art. Eur J Radiol 83(3):429–437
- 6. Barr RG, Managuli RA (2019) A clinical study comparing the diagnostic performance of assist strain ratio against manual strain ratio in ultrasound breast elastography. Ultrasound Q 35(1):82–87
- <span id="page-8-5"></span>7. Barr RG, Zhang Z (2015) Shear-wave elastography of the breast: value of a quality measure and comparison with strain elastography. Radiology 275(1):45–53
- <span id="page-8-4"></span>8. Suvannarerg V, Chitchumnong P, Apiwat W et al (2019) Diagnostic performance of qualitative and quantitative shear wave elastography in diferentiating malignant from benign breast masses, and association with the histological prognostic factors. Quant Imaging Med Surg 9(3):386–398
- <span id="page-8-6"></span>9. Athanasiou A, Tardivon A, Tanter M et al (2010) Breast lesions: quantitative elastography with supersonic shear imaging-preliminary results. Radiology 256(1):297–303
- 10. Tozaki M, Fukuma E (2011) Pattern classification of ShearWave<sup>TM</sup> elastography images for diferential diagnosis between benign and malignant solid breast masses. Acta radiol 52(10):1069–1075
- 11. Chang JM, Moon WK, Cho N et al (2011) Clinical application of shear wave elastography (SWE) in the diagnosis of benign and malignant breast diseases. Breast Cancer Res Treat 129(1):89–97
- 12. Evans A, Whelehan P, Thomson K et al (2010) Quantitative shear wave ultrasound elastography: initial experience in solid breast masses. Breast Cancer Res 12(6):R104
- 13. Berg WA, Cosgrove DO, Doré CJ et al (2012) Shear-wave elastography improves the specifcity of breast US: the BE1 multinational study of 939 masses. Radiology 262(2):435–449
- 14. Lee SH, Chang JM, Kim WH et al (2014) Added value of shearwave elastography for evaluation of breast masses detected with screening US imaging. Radiology 273(1):61–69
- 15. Au FWF, Ghai S, Moshonov H et al (2014) Diagnostic performance of quantitative shear wave elastography in the evaluation of solid breast masses: determination of the most discriminatory parameter. AJR Am J Roentgenol 203(3):W328–36
- <span id="page-8-7"></span>16. Evans A, Whelehan P, Thomson K et al (2012) Diferentiating benign from malignant solid breast masses: value of shear wave elastography according to lesion stifness combined with greyscale ultrasound according to BI-RADS classifcation. Br J Cancer 107(2):224–229
- <span id="page-8-8"></span>17. Erdoğan H, Durmaz MS, Özbakır B et al (2020) Experience of using shear wave elastography in evaluation of testicular stifness in cases of male infertility. J Ultrasound. [https://doi.org/10.1007/](https://doi.org/10.1007/s40477-020-00430-5) [s40477-020-00430-5](https://doi.org/10.1007/s40477-020-00430-5)
- 18. Kara T, Ateş F, Durmaz MS et al (2020) Assessment of thyroid gland elasticity with shear-wave elastography in Hashimoto's thyroiditis patients. J Ultrasound. [https://doi.org/10.1007/s4047](https://doi.org/10.1007/s40477-020-00437-y) [7-020-00437-y](https://doi.org/10.1007/s40477-020-00437-y)
- 19. Paternostro R, Reiberger T, Bucsics T (2019) Elastography-based screening for esophageal varices in patients with advanced chronic liver disease. World J Gastroenterol 25(3):308–329. [https://doi.](https://doi.org/10.3748/wjg.v25.i3.308) [org/10.3748/wjg.v25.i3.308](https://doi.org/10.3748/wjg.v25.i3.308)
- <span id="page-8-9"></span>20. Ozgokce M, Batur M, Alpaslan M et al (2019) A comparative evaluation of cataract classifcations based on shear-wave elastography and B-mode ultrasound fndings. J Ultrasound 22(4):447– 452.<https://doi.org/10.1007/s40477-019-00400-6>
- <span id="page-8-10"></span>21. Gheonea IA, Stoica Z, Bondari S (2011) Diferential diagnosis of breast lesions using ultrasound elastography. Indian J Radiol Imaging 21(4):301–305
- <span id="page-8-11"></span>22. Liu B, Zheng Y, Huang G et al (2016) Breast lesions: quantitative diagnosis using ultrasound shear wave elastography—a systematic review and meta-analysis. Ultrasound Med Biol 42(4):835–847
- 23. Luo J, Cao Y, Nian W et al (2018) Beneft of shear-wave elastography in the diferential diagnosis of breast lesion: a diagnostic meta-analysis. Med Ultrason 1(1):43–49
- <span id="page-8-12"></span>24. Xue Y, Yao S, Li X, Zhang H (2017) Value of shear wave elastography in discriminating malignant and benign breast lesions: a meta-analysis. Medicine 96(42):e7412
- <span id="page-8-13"></span>25. American College of Radiology (2013) ACR BI-RADS Atlas: Breast Imaging Reporting and Data System. Mammography, Ultrasound, Magnetic Resonance Imaging, Follow-up and Outcome Monitoring, Data Dictionary
- <span id="page-8-14"></span>26. Kim MY, Choi N, Yang JH, Yoo YB, Park KS (2015) False positive or negative results of shear-wave elastography in diferentiating benign from malignant breast masses: analysis of clinical and ultrasonographic characteristics. Acta Radiol 56(10):1155–1162
- <span id="page-8-15"></span>27. Yoon JH, Jung HK, Lee JT, Ko KH (2013) Shear-wave elastography in the diagnosis of solid breast masses: what leads to falsenegative or false-positive results? Eur Radiol 23(9):2432–2440
- <span id="page-8-16"></span>28. Alikhassi A, Azizi F, Ensani F (2020) Imaging features of granulomatous mastitis in 36 patients with new sonographic signs. J Ultrasound 23(1):61–68.<https://doi.org/10.1007/s40477-019-00392-3>
- <span id="page-8-17"></span>29. Carlino G, Rinaldi P, Giuliani M et al (2019) Ultrasound-guided preoperative localization of breast lesions: a good choice. J Ultrasound 22(1):85–94.<https://doi.org/10.1007/s40477-018-0335-0>

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional afliations.